BIOMAT Database Logo BIOMAT Database Logo

Sequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer. 1995

L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Department of Medical Oncology II, Regina Elena Institute for Cancer Research, Rome, Italy.

To determine the activity of sequential administration of thymopentin (TP-5), interferon alpha-2a (IFN) and interleukin-2 (IL-2) in metastatic renal cell cancer (RCC), 17 patients with RCC were treated with TP-5 50 mg/d on days 1 to 14, IFN 3 MIU/d on days 14, 15, 21, 22 and IL-2 18 MIU/d on days 16 to 20, and 23 to 27. Treatment was given subcutaneously and cycles were repeated every 6 weeks. All patients were assessed for toxicity and response. No objective responses were observed. Two patients had a short-lived disease stabilization. Median survival was 9 months. Toxicity was generally moderate. The most important side-effects were related to IL-2 administration. In view of the lack of antitumor activity, the combination of TP-5 + IFN + IL-2 in the doses and schedule used in this trial cannot be recommended. The investigation of chemotherapeutic and immunological agents that can effectively synergize with IFN or IL-2 is essential.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females

Related Publications

L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.
February 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
January 1994, European journal of cancer (Oxford, England : 1990),
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
September 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma.
January 1993, European journal of cancer (Oxford, England : 1990),
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma.
March 1997, International journal of oncology,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
September 1990, Annals of oncology : official journal of the European Society for Medical Oncology,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
[Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
January 1993, Wiener klinische Wochenschrift,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
September 1990, Molecular biotherapy,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
June 1994, British journal of cancer,
L Di Lauro, and P Del Medico, and S Carpano, and A Cancrini, and T Gionfra, and P Vici, and M Rosselli, and M Lopez
Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine.
December 1991, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!